TCB-2 is a
hallucinogen discovered in 2006 by Thomas McLean working in the lab of
David Nichols at
Purdue University.[1] It is a
conformationally-restricted
derivative of the
phenethylamine2C-B, also a hallucinogen, and acts as a
potentagonist for the
5-HT2A and
5-HT2Creceptors with a
Ki of 0.26 nM at the human 5-HT2A receptor. In drug-substitution experiments in rats, TCB-2 was found to be of similar potency to both
LSD and
Bromo-DragonFLY, ranking it among the most potent phenethylamine hallucinogens yet discovered.[1] This high potency and selectivity has made TCB-2 useful for distinguishing 5-HT2A mediated responses from those produced by other similar receptors.[2] TCB-2 has similar but not identical effects in animals to related phenethylamine hallucinogens such as
DOI, and has been used for studying how the function of the 5-HT2A receptor differs from that of other
serotonin receptors in a number of animal models, such as studies of
cocaine addiction and
neuropathic pain.[3][4][5][6]
^Fox MA, French HT, LaPorte JL, Blackler AR, Murphy DL (September 2010). "The serotonin 5-HT(2A) receptor agonist TCB-2: a behavioral and neurophysiological analysis". Psychopharmacology. 212 (1): 13–23.
doi:
10.1007/s00213-009-1694-1.
PMID19823806.
S2CID22499760.
^Aira Z, Buesa I, Salgueiro M, Bilbao J, Aguilera L, Zimmermann M, Azkue JJ (July 2010). "Subtype-specific changes in 5-HT receptor-mediated modulation of C fibre-evoked spinal field potentials are triggered by peripheral nerve injury". Neuroscience. 168 (3): 831–41.
doi:
10.1016/j.neuroscience.2010.04.032.
PMID20412834.
S2CID207248287.
^Katsidoni V, Apazoglou K, Panagis G (February 2011). "Role of serotonin 5-HT2A and 5-HT2C receptors on brain stimulation reward and the reward-facilitating effect of cocaine". Psychopharmacology. 213 (2–3): 337–54.
doi:
10.1007/s00213-010-1887-7.
PMID20577718.
S2CID1580337.
TCB-2 is a
hallucinogen discovered in 2006 by Thomas McLean working in the lab of
David Nichols at
Purdue University.[1] It is a
conformationally-restricted
derivative of the
phenethylamine2C-B, also a hallucinogen, and acts as a
potentagonist for the
5-HT2A and
5-HT2Creceptors with a
Ki of 0.26 nM at the human 5-HT2A receptor. In drug-substitution experiments in rats, TCB-2 was found to be of similar potency to both
LSD and
Bromo-DragonFLY, ranking it among the most potent phenethylamine hallucinogens yet discovered.[1] This high potency and selectivity has made TCB-2 useful for distinguishing 5-HT2A mediated responses from those produced by other similar receptors.[2] TCB-2 has similar but not identical effects in animals to related phenethylamine hallucinogens such as
DOI, and has been used for studying how the function of the 5-HT2A receptor differs from that of other
serotonin receptors in a number of animal models, such as studies of
cocaine addiction and
neuropathic pain.[3][4][5][6]
^Fox MA, French HT, LaPorte JL, Blackler AR, Murphy DL (September 2010). "The serotonin 5-HT(2A) receptor agonist TCB-2: a behavioral and neurophysiological analysis". Psychopharmacology. 212 (1): 13–23.
doi:
10.1007/s00213-009-1694-1.
PMID19823806.
S2CID22499760.
^Aira Z, Buesa I, Salgueiro M, Bilbao J, Aguilera L, Zimmermann M, Azkue JJ (July 2010). "Subtype-specific changes in 5-HT receptor-mediated modulation of C fibre-evoked spinal field potentials are triggered by peripheral nerve injury". Neuroscience. 168 (3): 831–41.
doi:
10.1016/j.neuroscience.2010.04.032.
PMID20412834.
S2CID207248287.
^Katsidoni V, Apazoglou K, Panagis G (February 2011). "Role of serotonin 5-HT2A and 5-HT2C receptors on brain stimulation reward and the reward-facilitating effect of cocaine". Psychopharmacology. 213 (2–3): 337–54.
doi:
10.1007/s00213-010-1887-7.
PMID20577718.
S2CID1580337.